GSK inaugurates HUF 3 bln production unit in Hungary
The Hungarian unit of British drugmaker GlaxoSmithKline (GSK) inaugurated a HUF 3 billion production unit at its vaccine plant in Gödöllő, near Budapest, yesterday, according to Hungarian news agency MTI.
The production unit will turn out components for diphtheria and tetanus vaccines.
The new unit will produce 130 million units annually, said GSK managing director Christopher Hunley. He also acknowledged the importance of the companyʼs partnerships with the Hungarian government as well as local universities and other educational institutions.
U.K. ambassador to Hungary Iain Lindsay said GSK laid the foundations for stable business growth in Hungary thanks to the stable economy and a favorable environment for doing business.
Minister of Foreign Affairs and Trade Péter Szijjártó noted that GSK was one of four British companies with whom the government signed strategic agreements earlier.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.